Fibromyalgia - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2017, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 6, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibromyalgia - Overview
Fibromyalgia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibromyalgia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibromyalgia - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Daiichi Sankyo Company Ltd
Immune Therapeutics Inc
Innovative Med Concepts LLC
Jiangsu Hengrui Medicine Co Ltd
KPI Therapeutics Inc
Merck & Co Inc
Pfizer Inc
SWITCH Biotech LLC
Theravance Biopharma Inc
Vitality Biopharma Inc
Zynerba Pharmaceuticals Inc
Fibromyalgia - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1069562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-8062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirogabalin besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirtazapine ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SWT-06101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-9855 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibromyalgia - Dormant Projects
Fibromyalgia - Discontinued Products
Fibromyalgia - Product Development Milestones
Featured News & Press Releases
Oct 17, 2016: Zynerba Provides Clinical Update for Lead Development Candidate ZYN001
Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study
Apr 30, 2014: Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia
Dec 04, 2012: Theravance Initiates Phase II Study With TD-9855 For Treatment Of Fibromyalgia
Nov 27, 2012: Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin
Nov 19, 2012: Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia
Jul 23, 2012: Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder
Feb 02, 2009: UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Fibromyalgia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Fibromyalgia - Pipeline by Astellas Pharma Inc, H1 2017
Fibromyalgia - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Fibromyalgia - Pipeline by Immune Therapeutics Inc, H1 2017
Fibromyalgia - Pipeline by Innovative Med Concepts LLC, H1 2017
Fibromyalgia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Fibromyalgia - Pipeline by KPI Therapeutics Inc, H1 2017
Fibromyalgia - Pipeline by Merck & Co Inc, H1 2017
Fibromyalgia - Pipeline by Pfizer Inc, H1 2017
Fibromyalgia - Pipeline by SWITCH Biotech LLC, H1 2017
Fibromyalgia - Pipeline by Theravance Biopharma Inc, H1 2017
Fibromyalgia - Pipeline by Vitality Biopharma Inc, H1 2017
Fibromyalgia - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
Fibromyalgia - Dormant Projects, H1 2017
Fibromyalgia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Fibromyalgia - Discontinued Products, H1 2017